Related Experiment Video

Updated: Nov 4, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

A comparative molecular dynamic simulation study on potent ligands targeting mTOR/FRB domain for breast cancer

Varruchi Sharma1, Anil Panwar2, Anupam Sharma3

  • 1Depatment of Biotechnology, Sri Guru Gobind Singh College, Chandigarh, India.

Biotechnology and Applied Biochemistry
|May 31, 2021
PubMed

Insights

Researchers developed a new drug candidate, LIG2, to target the mechanistic target of rapamycin (mTOR/FRB) domain, offering potential therapeutic implications for breast cancer treatment.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • The mechanistic target of rapamycin (mTOR/FRB) domain is crucial in breast cancer progression.
  • The phosphoinositide 3 kinase/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway plays a vital role in disease etiology.

Purpose of the Study:

  • To develop and identify the optimal drug candidate targeting the mTOR/FRB domain for breast cancer therapy.
  • To investigate the potential of novel ligands as antagonists for the mTOR/FRB domain.

Main Methods:

  • Structure-based drug design was employed to identify and develop drug candidates.
  • Protein structure generation using I-TASSER, ligand design with Chemsketch and Ligbuilder.
  • Ligand validation through bioavailability, toxicity assessments, and molecular dynamic simulations.

Main Results:

  • Ligand 2 (LIG2) demonstrated superior stability compared to Ligand 3 (LIG3) in molecular dynamic simulations.
  • Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF) analyses confirmed LIG2's enhanced complex stability.
  • LIG2 exhibits potential antagonistic properties against the mTOR/FRB domain.

Conclusions:

  • LIG2 is a stable and promising drug candidate for targeting the mTOR/FRB domain.
  • The developed drug candidate holds significant therapeutic potential for treating breast cancer.
Keywords:
FRB domainPI3K/AKT/mTOR pathwaybreast cancerinhibitorsstructure-based drug designing

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K